Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manon Cox

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Vaccine|March 29, 2017
Modern technology: The preferred biosecurity strategy?Manon Cox
Human Vaccines & Immunotherapeutics|July 19, 2022
2021 ISV Annual Virtual CongressManon Cox
Human Vaccines & Immunotherapeutics|July 7, 2015
My passion is to drive innovation in vaccine developmentManon Cox
Journal of Commercial Biotechnology|March 29, 2020
What to do when your technology is good but a licence is terminatedManon Cox, Dan Adams
Human Vaccines & Immunotherapeutics|July 19, 2022
Meet the fellows: Everything about ISVDenise Doolan, Shan Lu, Ted Ross, et al.
Vaccine|November 3, 2009
Development of a simple and high-yielding fed-batch process for the production of influenza vaccinesJamal Meghrous, Wafaa Mahmoud, Danielle Jacob, et al.
Plos One|April 20, 2017
Complete study demonstrating the absence of rhabdovirus in a distinct Sf9 cell lineYoshifumi Hashimoto, Daniel Macri, Indresh Srivastava, et al.
Vaccine|February 25, 2006
A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in miceZhimin Zhou, Penny Post, Rick Chubet, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 15, 2016
Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin AdjuvantClifton McPherson, Richard Chubet, Kathy Holtz, et al.
Pediatrics|April 4, 2018
Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized TrialLisa M Dunkle, Ruvim Izikson, Peter A Patriarca, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Vaccine|March 29, 2017
Modern technology: The preferred biosecurity strategy?Manon Cox
Human Vaccines & Immunotherapeutics|July 19, 2022
2021 ISV Annual Virtual CongressManon Cox
Human Vaccines & Immunotherapeutics|July 7, 2015
My passion is to drive innovation in vaccine developmentManon Cox
Journal of Commercial Biotechnology|March 29, 2020
What to do when your technology is good but a licence is terminatedManon Cox, Dan Adams
Human Vaccines & Immunotherapeutics|July 19, 2022
Meet the fellows: Everything about ISVDenise Doolan, Shan Lu, Ted Ross, et al.
Vaccine|November 3, 2009
Development of a simple and high-yielding fed-batch process for the production of influenza vaccinesJamal Meghrous, Wafaa Mahmoud, Danielle Jacob, et al.
Plos One|April 20, 2017
Complete study demonstrating the absence of rhabdovirus in a distinct Sf9 cell lineYoshifumi Hashimoto, Daniel Macri, Indresh Srivastava, et al.
Vaccine|February 25, 2006
A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in miceZhimin Zhou, Penny Post, Rick Chubet, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 15, 2016
Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin AdjuvantClifton McPherson, Richard Chubet, Kathy Holtz, et al.
Pediatrics|April 4, 2018
Safety and Immunogenicity of a Recombinant Influenza Vaccine: A Randomized TrialLisa M Dunkle, Ruvim Izikson, Peter A Patriarca, et al.
Pageof 2